STOCK TITAN

Eli Lilly & Co. - LLY STOCK NEWS

Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.

Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.

Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.

The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.

Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Eli Lilly and Company to announce Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
-
Rhea-AI Summary
Eli Lilly announces five-year outcomes from the monarchE study, showing the long-term benefits of adjuvant Verzenio treatment in patients with early breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary
Patients with moderate-to-severe atopic dermatitis who continued treatment with lebrikizumab for up to two years experienced sustained skin clearance and itch relief, according to the ADjoin long-term extension study. Lebrikizumab is an interleukin-13 inhibitor that specifically blocks IL-13 signaling. The study showed durable efficacy in skin and itch outcomes through two years of treatment with both monthly and two-week dosing. The safety profile of lebrikizumab was consistent with previous studies, with no new safety signals observed. Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Summary
Eli Lilly's tirzepatide shows significant weight loss in SURMOUNT-3 trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary
Mirikizumab demonstrates positive results in Phase 3 trial for Crohn's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
Rhea-AI Summary
Eli Lilly and Company to present data on Verzenio, Retevmo, and imlunestrant at the 2023 ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
-
Rhea-AI Summary
Loxo@Lilly to present preclinical data on new oncology agents at conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
News
Rhea-AI Summary
Eli Lilly and Company announces changes to its executive leadership team. Mike Mason, EVP and President of Lilly Diabetes and Obesity, will retire at the end of 2023. Patrik Jonsson will assume leadership of Lilly Diabetes and Obesity. Daniel Skovronsky takes on the additional role of President of Lilly Immunology. Leigh Ann Pusey, EVP of Corporate Affairs and Communications, will leave the company. David Hyman becomes Lilly's Chief Medical Officer. Mark Genovese joins as SVP of Immunology Development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
management
Rhea-AI Summary
Eli Lilly and Company to acquire POINT Biopharma Global, Inc. for $1.4 billion, expanding its radioligand therapy pipeline for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags

FAQ

What is the current stock price of Eli Lilly & Co. (LLY)?

The current stock price of Eli Lilly & Co. (LLY) is $746.2 as of November 15, 2024.

What is the market cap of Eli Lilly & Co. (LLY)?

The market cap of Eli Lilly & Co. (LLY) is approximately 713.4B.

What are Eli Lilly's core business areas?

Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology.

What are some of Eli Lilly's key products?

Key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes, and Taltz and Olumiant for immunology.

How did Eli Lilly perform financially in Q1 2024?

Eli Lilly reported a 26% year-over-year increase in revenue to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

What recent investments has Eli Lilly made?

Eli Lilly has invested $5.3 billion to expand its manufacturing site in Lebanon, Indiana, supporting the production of treatments for chronic diseases like obesity and type 2 diabetes.

Who is the new Executive Vice President of Global Quality at Eli Lilly?

Melissa Seymour has been appointed as the new Executive Vice President of Global Quality, effective July 22, 2024.

What are some recent clinical trial results shared by Eli Lilly?

Eli Lilly shared positive results from trials for insulin efsitora alfa, Verzenio, Retevmo, olomorasib, and imlunestrant, showcasing their advancements in treatments for diabetes and cancer.

In how many countries does Eli Lilly operate?

Eli Lilly operates in 18 countries and its products are sold in approximately 125 countries.

What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?

The investment will enhance production capacity for essential treatments like Zepbound and Mounjaro, aiming to meet the growing demand for these medicines.

What is the focus of Eli Lilly's ongoing research and development?

Eli Lilly's R&D focuses on innovative solutions for diabetes care, obesity, Alzheimer's disease, immune disorders, and cancer.

What are some common side effects of Eli Lilly's product Mounjaro?

Common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Eli Lilly & Co.

NYSE:LLY

LLY Rankings

LLY Stock Data

713.43B
950.41M
0.15%
83.46%
0.64%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
INDIANAPOLIS